Combined injection of 18F-fluorodeoxyglucose and 3′-Deoxy-3′-[18F]fluorothymidine PET achieves more complete identification of viable lung cancer cells in mice and patients than individual radiopharmaceutical: A proof-of-concept study

Translational Oncology

Volumn 6, Issue 6, 2013, Pages 775-783

  Li, Xiao Feng ^a   Huang, Tao ^a,b   Jiang, Huijie ^a,c   Wang, Xuemei ^d   Shen, Baozhong ^b   Wang, Xiangcheng ^d   Ng, Chin K ^a   Postel, Gregory C ^a   Civelek, A Cahid ^a  

^a University of Louisville School of Medicine   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^d Affiliated Hospital of Inner Mongolia Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; BROXURIDINE; FLUORODEOXYGLUCOSE F 18; PIMONIDAZOLE; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY;

EID: 84891665902     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13577     Document Type: Article

References (38)

1. 18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging 39, 846-851.
2. Nakajo M, Nakajo M, Kajiya Y, Jinguji M, Mori S, Aridome K, Suenaga T, and Tanaka S (2012). High FDG and low FLT uptake in a thyroid papillary carcinoma incidentally discovered by FDG PET/CT. Clin Nucl Med 37, 607-608.
3. 18F]fluorothymidine positron emission tomography. J Clin Oncol 29, 1701-1708.
4. 18F-FLT PET in non-small cell lung cancer. J Nucl Med 51, 1870-1877.
5. 18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 37, 1291-1299.
6. 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34, 1610-1616.
7. 18F-FDG. J NuclMed 44, 1426-1431.
8. Burgman P, O'Donoghue JA, Humm JL, and Ling CC (2001). Hypoxiainduced increase in FDG uptake in MCF7 cells. J Nucl Med 42, 170-175.
9. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, and Humm JL (2005). Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 62, 545-553.
10. 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med 5, 632-638.
11. 64Cu-ATSM in a rodent model of cancer. Nucl Med Biol 35, 713-720.
12. Mudd SR, Holich KD, Voorbach MJ, Cole TB, Reuter DR, Tapang P, Bukofzer G, Chakravartty A, Donawho CK, Palma JP, et al. (2012). Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model. Mol Imaging Biol 14, 617-624.
13. Thomlinson RH and Gray LH (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9, 539-549.
14. Graves EE, Maity A, and Le QT (2010). The tumor microenvironment in nonsmall cell lung cancer. Semin Radiat Oncol 20, 156-163.
15. Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
16. Li XF, Carlin S, Urano M, Russell J, Ling CC, and O'Donoghue JA (2007). Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 67, 7646-7653.
17. Kennedy AS, Raleigh JA, Perez GM, Calkins DP, Thrall DE, Novotny DB, and Varia MA (1997). Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 37, 897-905.
18. Durand RE and Raleigh JA (1998). Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 58, 3547-3550.
19. 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. J Nucl Med 53, 1262-1268.
20. Clavo AC, Brown RS, and Wahl RL (1995). Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 36, 1625-1632.
21. Dierckx RA and Van de Wiele C (2008). FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 35, 1544-1549.
22. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging 39, 262-270.
23. 18F-fluoride for PET assessment of metastatic bone disease. Eur J Nucl Med Mol Imaging 40, 1141-1145.
24. 131I-IAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging 37, 339-348.
25. Li XF and O'Donoghue JA (2008). Hypoxia in microscopic tumors. Cancer Lett 264, 172-180.
26. Li XF, Jiang H, Ma Y, Huang T, Yin X, Civelek AC, and Shen B (2013). A model system for validation of PET radiopharmaceuticals: focusing on tumor microenvironment. Int J Med Phys Clin Eng Radiat Oncol 2, 19-29 doi: 10. 4236/ijmpcero. 2013. 21004.
27. Li XF, Ma Y, and Jiang H (2012). Understanding hypoxia microenvironment of micro-metastases. J Solid Tumors 2 (2), 28-33. doi: 10. 5430/jst. v2n2p28.
28. 18F-FDG is a surrogate marker of therapy response and tumor recovery after drug withdrawal during treatment with a dual PI3K/mTOR inhibitor in a preclinical model of cisplatin-resistant ovarian cancer. Transl Oncol 6, 586-595.
29. Kayed H, Meyer P, He Y, Kraenzlin B, Fink C, Gretz N, Schoenberg SO, and Sadick M (2012). Evaluation of the metabolic response to cyclopamine therapy in pancreatic cancer xenografts using a clinical PET-CT system. Transl Oncol 5, 335-343.
30. 18F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Transl Oncol 4, 241-248.
31. Kinahan PE, Doot RK, Wanner-Roybal M, Bidaut LM, Armato SG, Meyer CR, and McLennan G (2009). PET/CT assessment of response to therapy: tumor change measurement, truth data, and error. Transl Oncol 2, 223-230.
32. Honer M, Ebenhan T, Allegrini PR, Ametamey SM, Becquet M, Cannet C, Lane HA, O'Reilly TM, Schubiger PA, Sticker-Jantscheff M, et al. (2010). Anti-angiogenic/vascular effects of the mTOR inhibitor everolimus are not detectable by FDG/FLT-PET. Transl Oncol 3, 264-275.
33. 18F-FLT in non-small cell lung cancer tumor xenografts by micro-PET. J Nucl Med 53 (suppl 1), 1136.
34. 18F-FDG distribution in patients with cancer. J Clin Oncol 30 (suppl), abstr e21149.
35. 18F-FDG accumulation in untreated lung cancers in human subjects and mice. J Nucl Med 54 (suppl 2), 173.
36. Ljungkvist AS, Bussink J, Kaanders JH, Rijken PF, Begg AC, Raleigh JA, and van der Kogel AJ (2005). Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys 62, 1157-1168.
37. 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 70, 235-242.
38. Kadrmas DJ, Rust TC, and Hoffman JM (2013). Single-scan dual-tracer FLT+FDG PET tumor characterization. Phys Med Biol 58, 429-449.